Azacitidine maintenance therapy after allogeneic stem cell transplantation for CML (VZ-CML-PI-0130).

Trial Profile

Azacitidine maintenance therapy after allogeneic stem cell transplantation for CML (VZ-CML-PI-0130).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Azacitidine (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Methotrexate; Tacrolimus
  • Indications Chronic myeloid leukaemia; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record..
    • 30 Sep 2014 Trial status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2014 According to NCT record; status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top